A picture containing object, clock, monitor, screen

Description automatically generated

BetterLife Files Patent for Invention of Novel Subcutaneous Implant to Prevent Drug Diversion of LSD and Other Psychedelic Drugs

VANCOUVER, British Columbia, April 29, 2021 - BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: [BETR](https://thecse.com/en/listings/life-sciences/betterlife-pharma-inc) / OTCQB: [BETRF](https://www.otcmarkets.com/stock/BETRF/overview) / FRA: [NPAU](https://www.tradegate.de/orderbuch.php?lang=en&isin=CA08772P2026)), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that it has applied for patent protection of its novel implantable subcutaneous product and its use in the prevention of psychedelic drug diversion.

LSD and psilocybin microdosing are currently in multiple ongoing clinical trials.  One major overlooked issue is the possibility of the patient in consuming a full psychedelic dose of Psilocybin or LSD as opposed to the prescribed microdose or resale of the drugs to someone other than the patient.  BetterLife's invention has solved this problem by use of an implant administered by in-office procedure performed by a physician.  The technical specification includes the option for a pulsatile release in accordance with current microdosed psychedelic protocols as well as an extended duration of release.

Ahmad Doroudian, CEO of BetterLife, commented, “Controlled substances, including but not limited to psychedelic drugs such as LSD and psylocibin have recently become of interest for the treatment of mental health disorders among other medical indications. A problem associated with the dispensing of controlled substances is the risk of the patient self-administering a larger dose than prescribed. This can result in addiction, intoxication, overdose, and possibly death. The application of our novel implantable subcutaneous product will enable widespread use of such drugs without the associated risks of unintentional mis-dosing or intentional diversion.”

BetterLife’s novel implantable subcutaneous product allows for the administration of one or more drugs. It can be potentially used for extended release or other controlled release needs. In addition to overcoming the drug diversion issue, it will potentially greatly assist in reducing the burden on patients as well as associated healthcare costs for certain repeat dosing treatments.

**About BetterLife Pharma**

BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next generation psychedelic products for the treatment of mental disorders. Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus.

For further information please visit [www.abetterlifepharma.com](file:///C:\Users\andre\AppData\Local\Temp\www.abetterlifepharma.com).

**Contact**

**Ahmad Doroudian**, Chief Executive Officer

Email: [ahmad.doroudian@blifepharma.com](mailto:ahmad.doroudian@blifepharma.com)

Phone: 604-221-0595

**Cautionary Note Regarding Forward-Looking Statements**

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.